Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine

Viruses. 2024 Jun 11;16(6):942. doi: 10.3390/v16060942.

Abstract

The thermostability of vaccines, particularly enveloped viral vectored vaccines, remains a challenge to their delivery wherever needed. The freeze-drying of viral vectored vaccines is a promising approach but remains challenging due to the water removal process from the outer and inner parts of the virus. In the case of enveloped viruses, freeze-drying induces increased stress on the envelope, which often leads to the inactivation of the virus. In this study, we designed a method to freeze-dry a recombinant vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike glycoprotein. Since the envelope of VSV is composed of 50% lipids and 50% protein, the formulation study focused on both the protein and lipid portions of the vector. Formulations were prepared primarily using sucrose, trehalose, and sorbitol as cryoprotectants; mannitol as a lyoprotectant; and histidine as a buffer. Initially, the infectivity of rVSV-SARS-CoV-2 and the cake stability were investigated at different final moisture content levels. High recovery of the infectious viral titer (~0.5 to 1 log loss) was found at 3-6% moisture content, with no deterioration in the freeze-dried cakes. To further minimize infectious viral titer loss, the composition and concentration of the excipients were studied. An increase from 5 to 10% in both the cryoprotectants and lyoprotectant, together with the addition of 0.5% gelatin, resulted in the improved recovery of the infectious virus titer and stable cake formation. Moreover, the secondary drying temperature of the freeze-drying process showed a significant impact on the infectivity of rVSV-SARS-CoV-2. The infectivity of the vector declined drastically when the temperature was raised above 20 °C. Throughout a long-term stability study, formulations containing 10% sugar (sucrose/trehalose), 10% mannitol, 0.5% gelatin, and 10 mM histidine showed satisfactory stability for six months at 2-8 °C. The development of this freeze-drying process and the optimized formulation minimize the need for a costly cold chain distribution system.

Keywords: COVID-19; CPPs; CQAs; VSV; enveloped viral vector vaccine; freeze-drying; rVSV-SARS-CoV-2; solid formulation; stability; vesicular stomatitis virus; viral vaccine bioprocess.

MeSH terms

  • Animals
  • COVID-19 / prevention & control
  • COVID-19 / virology
  • COVID-19 Vaccines* / chemistry
  • COVID-19 Vaccines* / immunology
  • Chlorocebus aethiops
  • Cryoprotective Agents* / chemistry
  • Cryoprotective Agents* / pharmacology
  • Drug Stability
  • Freeze Drying* / methods
  • Histidine / chemistry
  • Humans
  • Mannitol / chemistry
  • SARS-CoV-2* / chemistry
  • SARS-CoV-2* / immunology
  • Sorbitol / chemistry
  • Spike Glycoprotein, Coronavirus* / chemistry
  • Spike Glycoprotein, Coronavirus* / immunology
  • Sucrose / chemistry
  • Trehalose / chemistry
  • Vaccines, Synthetic / chemistry
  • Vaccines, Synthetic / immunology
  • Vero Cells
  • Vesicular stomatitis Indiana virus / genetics

Substances

  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • Cryoprotective Agents
  • Trehalose
  • Mannitol
  • spike protein, SARS-CoV-2
  • Sucrose
  • Sorbitol
  • Histidine
  • Vaccines, Synthetic